Axsome Therapeutics, Inc.

- The provided document (pages 4-15) does not mention any current or planned fundraising activities through debt or equity. - The focus is on commercial execution, product launches (AUVELITY in Alzheimer’s agitation), pipeline progress, and business development. - Financial discussions highlight revenue growth, operating leverage, and managing SG&A expenses but do not reveal plans for raising capital. - Past acquisitions (e.g., SUNOSI) are referenced but no new fundraising strategies are detailed. - Long-term financial goals include achieving cash flow positivity and profitability, indicating attention to financial discipline rather than immediate capital raises.

- No specific details on current or future capital expenditures (capex) or strategic investments are explicitly mentioned in the document. - The company is primarily focused on commercial execution, including expanding their sales force and marketing activities (e.g., AUVELITY and SYMBRAVO launches). - Investment efforts appear directed towards clinical development with several Phase III trials planned or ongoing (e.g., AXS-12, AXS-05, Solriamfetol programs, AXS-20 in late-stage development). - Acquisition history noted (e.g., SUNOSI acquisition), but current focus remains on pipeline and commercialization rather than new acquisitions. - Expansion of commercial infrastructure includes increased sales teams for SYMBRAVO and AUVELITY, indicating operational investments. - Cash balance of $305 million expected to fund operations through to cash flow positivity, suggesting no major unannounced capital projects at this time.

- AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from Major Depressive Disorder (MDD) and Alzheimer’s disease (AD) agitation indications. - Continued growth expected for AUVELITY driven by expanded sales force (~630 reps) targeting 68,000 HCPs across multiple specialties and care settings. - Anticipated strong uptake from ongoing awareness campaigns, improved payer coverage (86% total coverage), and early frontline prescribing shifts. - SUNOSI revenue growing steadily, with 16% year-over-year growth in Q1 2026 and stable payer coverage (~83%). - SYMBRAVO showing 36% growth compared to Q4 2025, with sales force expansion and increasing primary care use. - Overall, revenue growth anticipated to continue, with operating leverage improving as top-line revenue outpaces operating expense growth. - Cautious near-term forecasting on Alzheimer’s Disease Agitation (ADA) uptake, but belief in transitory Q1 seasonality and robust longer-term ramp.

- Focus currently remains on revenue growth as the top priority. - Next goals after revenue growth are achieving cash flow positivity, followed by profitability. - Operating leverage expected as top-line revenue growth is anticipated to outpace operating expenses. - SG&A expenses likely to increase in Q2 2026 but at a slower rate, then level out. - Peak sales guidance: AUVELITY at least $8 billion, SUNOSI $300-$500 million, SYMBRAVO $500 million to $1 billion. - Expansion in sales force and market access expected to support continued strong revenue growth. - AUVELITY’s approval in two indications provides a clear line of sight to significant market potential. - IRA negotiations potentially impacting AUVELITY from 2031 onwards; current $8 billion peak estimate accounts for this. - Profitability is a mid-term goal, following revenue growth and cash flow positivity.

The document does not explicitly mention current, expected orderbook, or pending orders. However, related commercial progress and expectations include: - AUVELITY sales and launch efforts ongoing for Major Depressive Disorder (MDD) and new Alzheimer’s Disease Agitation (ADA) indication. - Expanded sales force calling on approximately 68,000 healthcare providers, targeting both MDD and ADA patients. - Strong growth in new patient starts and prescription activations expected to continue. - SYMBRAVO sales team expanded by 50 reps, payer coverage for 17 million lives secured. - SUNOSI maintains approximately 83% payer coverage, with 54,000 prescriptions written in Q1 2026 (16% YoY growth). - Preparations underway for ADA launch with final sales and marketing resources being finalized. - Anticipated incremental growth from ADA launch with uncertain but optimistic uptake over next 2-3 years. No specific numeric orderbook or pending order details disclosed.